Tuesday Morning Corp. (TUES) Jumps 12.55% on January 26

Equities Staff |

Tuesday Morning Corp. (TUES) was among the biggest gainers on the Russell 2000 for Tuesday January 26 as the stock popped 12.55% to $6.01, representing a gain of $0.67 per share. Some 814,772 shares traded hands on 4,026 trades, compared with an average daily volume of 619,864 shares out of a total float of 44.33 million. The stock opened at $5.36 and traded with an intraday range of $6.02 to $5.25.

After today's gains, Tuesday Morning Corp. reached a market cap of $266.4 million. Tuesday Morning Corp. has had a trading range between $21.52 and $4.86 over the last year, and it had a 50-day SMA of $6.13 and a 200-day SMA of $9.30.

The stock has a P/E Ratio of 21.4.

Tuesday Morning Corp is a retailer of off-price, upscale decorative home accessories, housewares, seasonal goods and maker gifts.

Tuesday Morning Corp. is based out of Dallas, TX and has some 8,820 employees. Its CEO is Steven R. Becker.

For a complete fundamental analysis analysis of Tuesday Morning Corp., check out Equities.com’s Stock Valuation Analysis report for TUES. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.



DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Comments

Emerging Growth

Immunovaccine Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.

Private Markets

Voleo

Voleo is a free download that allows you to form investment clubs with your friends, family, colleagues, classmates, teammates…basically anyone you know and trust. Invest and manage a stock portfolio…

Quants Inc

Quants, Inc, a California Corporation, develops, markets and operates financial technology platforms and alternative investment products offering sophisticated risk management since 2010. The Company has primarily sharpened its focus with…